Drug Eluting Stent Implantation for High Risk Patients and Novel Technologies in Percutaneous Coronary Intervention
07 / 2005 - 02 / 2010
Recent studies show that the local application of antiproliferative drugs for prevention of restenosis via a stent delivery system inhibits or reduces restenosis successfully. In the era of drug-eluting stents (DES), percutaneous coronary intervention has become a therapeutic option of choice. Especially, sirolimus and paclitaxel are used as safe, antiproliferative drugs. However, in-stent restenosis still remains a problem. Other dark sides of DES include: early and late stent thrombosis; increasing neo-intima with time; incomplete stent apposition; and stent fracture. As DES consist of a drug, a polymer, and a stent platform, several drugs with durable or erodable polymers and some kinds of platform have been tested. In his PhD project, Shuzou Tanimoto investigates the efficacy of new technologies and devices. In addition, he analyzes the long-term outcome and safety of new DES.